Biotech companies defied the gravitational pull of the global capital markets during the second quarter, as some of the major biotech indices finished in positive territory while other financial benchmarks declined.
The BioCentury 100 Index ended the quarter up 3.7%. The NASDAQ Biotechnology and AMEX Biotechnology indices also were up on the quarter, posting gains of 1.6% and 0.1%, respectively. The NASDAQ Composite Index was up 0.6%, while the AMEX Pharmaceutical Index was down 1.5%, the S&P 500 was down 3.2% and the Dow Jones Industrial Average lost 7.4% in the quarter.
source: BioCentury
